National
Cicilline fends off challenger in R.I. primary
Election results yield mixed bag for marriage equality prospects
Gay Rep. David Cicilline defeated his challenger in the Rhode Island Democratic primary on Tuesday. (Blade file photo by Michael Key)
Gay Rep. David Cicilline (D-R.I.) defeated his challenger, businessman Anthony Gemma, to win the Democratic nomination to continue to represent Rhode Island’s 1st congressional district in the U.S. House in Tuesday’s primary.
Local media outlets called the race for Cicilline about an hour after polls closed at 8 p.m. in Rhode Island. With 98 percent of precincts reporting, Cicilline held 61 percent of the vote, compared to the 31 percent claimed by Gemma and 8 percent won by another candidate, Chris Young.
Cicilline faced criticism during the race — even though he’s running in a overwhelmingly “blue” state — as a result of financial difficulties facing the city of Providence, R.I., where Cicilline served as mayor before running for Congress.
A report commissioned by the City Council last year blamed Cicilline’s administration for a lack of transparency and for making a series of moves – like tapping into Providence’s rainy-day fund – without councilors’ approval. The lawmaker apologized in April, saying he should have been more forthright about the financial condition of the city.
Still, Cicilline retained support heading into the primary. The lawmaker was once again endorsed by the Gay & Lesbian Victory Fund. In new campaign ads, former U.S. Rep. Patrick Kennedy, who once held the seat now held by Cicilline, vouched for the out lawmaker’s commitment to public service.
Sexual orientation did come into play during the Democratic primary. According to the Associated Press, Anthony Sionni, an unpaid campaign staffer for the Gemma campaign, compared the openly gay lawmaker on Twitter to convicted child molester and former Penn State coach Jerry Sandusky, saying there’s “nothing wrong with smearing a liar, thief, crook, Sandusky copy cat.” The state Democratic Party had called for Gemma to fire Anthony Sionni, apologize to Cicilline and disavow the message. In response, a Gemma campaign spokesperson reportedly said the tweet was “inappropriate” and Sionni agreed to leave the campaign.
Cicilline was running against a primary opponent who largely self-financed his campaign. According to Federal Election Commission reports, 80 percent of the $315,000 that Gemma raised was from him contributing or lending his money to his own campaign. In comparison, all the $1.7 million that Cicilline raised for his campaign was the result of outside contributions.
But Cicilline isn’t out of the woods in his bid to retain his U.S. House seat. He’s facing a challenge in the general election from Republican Brendan Doherty, a retired high-ranking police officer and former superintendent of Rhode Island’s Department of Public Safety.
According to a poll published by Rhode Island’s WPRI late last month, 52 percent of Gemma supporters said they’d back Doherty in the general election if the Democratic challenger lost the primary. Compared to the $1.7 million that Cicilline has raised, Doherty has $1.1 million in total net receipts. About five percent, or $50,000, of Doherty’s net receipts are from self-financing.
Chuck Wolfe, the Victory Fund’s CEO, said the choice is clear on LGBT issues heading into the general election because Doherty supports the Defense of Marriage Act, an anti-gay law that prohibits federal recognition of same-sex marriage.
“We’re pleased that Rhode Island Democrats have once again chosen David Cicilline to represent them in Congress,” Wolfe said. “Now voters will face a clear choice this November between a persistent champion for LGBT equality, and an opponent who supports the Defense of Marriage Act, which makes life harder for so many American families.”
The Victory Fund is citing the website Electful.com, which keeps track of candidates’ positions on issues, as the source for Doherty’s support for DOMA. On the other hand, Cicilline is an original co-sponsor of DOMA repeal legislation known as the Respect for Marriage Act.
The Democratic primary produced mixed results in terms of electing candidates who support marriage equality. One lesbian candidate, Laura Pisaturo, narrowly lost her bid to unseat a Democratic lawmaker who opposes same-sex marriage.
Many incumbent Democrats who support marriage equality fended off challenges from candidates who oppose it. Among those incumbents were State Sen. Ryan Pearson, State Rep. Arthur Handy, State Rep. Greg Amore, State Rep. Joseph Almeida, and State House Majority Whip Patrick O’Neill.
But in primaries in which pro-marriage equality challengers were running against incumbent Democrats who oppose it, the pro-LGBT side only won a single primary. Democrat Adam Satchell, a teacher and proponent of marriage equality, beat an incumbent Democrat who opposes same-sex marriage, State Sen. Michael Pinga.
Still, the outcome means a net gain of one vote in the State Senate at a time when legislation to enact same-sex marriage in the Ocean State is expected to advance next year.
In a competitive primary in State Senate District 29, incumbent State Sen. Michael McCaffrey, an opponent of marriage equality, won against Pisaturo, who was endorsed by the Victory Fund. McCaffrey had a narrow win against Pisaturo, taking 53 percent of the vote compared to Pisaturo’s 47 percent.
McCaffrey, chairs Rhode Island’s Senate Judiciary Committee, and, even though he’s a Democrat, has never allowed pending same-sex marriage legislation to advance in his committee. During a TV debate last month, McCaffrey said he “believes that marriage is between a man and a woman.”
Ray Sullivan, campaign director of Marriage Equality Rhode Island, said his organization is “incredibly proud” of the campaign Pisaturo waged despite her loss.
“We’re proud to have been a part of it,” Sullivan added. “She talked about issues that were important to people in that district, and if we had it to do all over again, we would absolutely stand with her.”
Asked whether marriage equality legislation can still advance, Sullivan said he intends to take McCaffrey “at his word” when the Democrat said during an earlier debate he’ll allow a vote on same-sex legislation in his committee despite his opposition to same-sex marriage.
“When we win a number of these races in the general election and we elect a pro-equality majority in the Senate in the general election, we expect Sen. McCaffrey to honor that commitment, and we look forward to scheduling a committee vote on marriage equality in the Senate Judiciary Committee,” Sullivan said.
In an interview with Washington Blade last week during the Democratic National Convention, Rhode Island Gov. Lincoln Chafee, a supporter of marriage equality, said the election of Pisaturo would be “pivotal” in determining whether same-sex marriage legislation would be able to advance in the Rhode Island legislature.
Other Senate races had disappointing outcomes for marriage equality proponents. Same-sex marriage opponent State Sen. Marc Cote won his primary against challenger Lewis Pryeor, who supports same-sex marriage. Similarly, marriage equality opponent State Sen. Daniel DaPonte won over challenger and marriage equality supporter Roberto DaSilva.
One race in which there was no incumbent also yielded a loss for marriage equality supporters. In State Senate District 26, Gene Dyszlewski, who supports marriage equality, lost to Frank Lombardi, who opposes same-sex marriage.
In State Senate District 33, David Gorman, a Democratic supporter of marriage equality, lost to Leonidas Raptakis, a Democratic opponent of gay nuptials. But the result in that race is a wash in that district because the incumbent Republican, State Sen. Glenford Shibley, opposes marriage equality.
According to WPRI, a group known as People for Rhode Island’s Future spent $26,500 earlier this month to elect six pro-marriage equality candidates in the Democratic primary. That group reportedly received a $20,000 donation to make that happen from Tim Gill, a gay Denver-based entrepreneur and philanthropist known for working to advance marriage equality, as well as $15,000 from Esmond Harmsworth, a Newport, R.I., resident and founding partner of Boston literary agency Zachary Shuster Harmsworth Literary Agency.
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
Holiday week brings setbacks for Trump-Vance trans agenda
Your guide to D.C.’s queer New Year’s Eve parties
Long-awaited ‘Pillion’ surpasses the sexy buzz
Reasons to be optimistic about 2026
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Using movement to boost your mental health during holidays
